Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

Core Viewpoint - Niagen Bioscience, Inc. has achieved a significant milestone by surpassing 300 material transfer agreements (MTAs) with global researchers, highlighting its leadership in NAD+ research and commitment to healthy aging [1] Company Summary - Niagen Bioscience, Inc. is recognized as the global authority on NAD+ (nicotinamide adenine dinucleotide) [1] - The company focuses on the science of healthy aging [1] - The external research program is considered the most extensive dedicated NAD+ research support program worldwide [1] Industry Summary - The milestone of 300 MTAs indicates a growing interest and investment in NAD+ research within the biotech industry [1] - The emphasis on healthy aging aligns with broader industry trends focusing on longevity and wellness [1]